The effects of heterogeneity on Simon Phase II clinical trial design operating characteristics
Christopher N Barnes1, Shesh N Rai2
1Department of Bioinformatics and Biostatistics, University of Louisville, 2Biostatistics Shared Facility, James Graham Brown Cancer Center, Louisville, Kentucky
Abstract: The homogeneity assumption of a Simon Phase II clinical trial is commonly violated due to excess variation in the response known as response heterogeneity. Using a general framework to model heterogeneity, we investigate its effects on the operating characteristics of the Simon trial design using the standard practice of averaging responses. We show that, under heterogeneity and averaging, the Simon designs have higher than expected errors which may result in false negative and false positive Phase II outcomes.
Keywords: Simon Trial, Phase II, heterogeneity
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.